Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 519Specimen Handling 382Carboplatin 374Magnetic Resonance Spectroscopy 337Cisplatin 328Nivolumab 309Cyclophosphamide 296Radiotherapy 256Paclitaxel 256Gemcitabine 235Biopsy 234Bevacizumab 213Dexamethasone 169durvalumab 166Oxaliplatin 162Rituximab 158Capecitabine 157Fluorouracil 148venetoclax 147Docetaxel 146Etoposide 141atezolizumab 140Drug Therapy 140Doxorubicin 134Ipilimumab 130Prednisone 120Lenalidomide 119Radiosurgery 118Leucovorin 112fludarabine 108

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cell Count × 1 year × Clear all
NCT07330050 2026-01-09

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
31 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡